Evonik's Restructuring Strategy Faces Critical Labor Negotiations

Evonik's €400M restructuring faces union pushback on wages, while market shifts in methionine and energy hedges signal operational improvement for the German chemical group.

The German specialty chemicals group Evonik finds its ambitious corporate overhaul intersecting with a significant challenge: tense wage negotiations. As management pushes forward with a major cost-cutting initiative, union representatives are meeting in Bad Breisig, demanding substantial pay increases. This clash over the company's future cost structure is unfolding just as the business shows tentative signs of operational improvement.

A Cost-Cutting Plan Under Pressure

Central to Evonik's strategy is the "Evonik Tailor Made" transformation program, designed to deliver annual savings of approximately €400 million by the end of 2026. A key component of this plan is the reduction of 2,000 positions globally. This objective now directly conflicts with the third round of collective bargaining for the chemical industry. Employers cite the sector's weak economic climate and persistently high energy costs. In contrast, the IGBCE union is insisting on wage hikes that outpace inflation. Every percentage point gained by labor representatives directly diminishes the intended savings from the corporate restructuring.

Operational Tailwinds Offer Contrasting Narrative

Away from the bargaining table, investors are receiving more encouraging signals. Barclays, the British investment bank, recently upgraded Evonik's stock to "overweight" and raised its price target to €17. Analysts attribute this optimism to a structural shift in the market for the amino acid methionine. Geopolitical tensions are placing pressure on Asian producers, leading global buyers to seek alternative sources. This dynamic is driving up spot prices in both China and Europe.

Furthermore, Evonik benefits from a favorable energy hedging position. Around 80% of its energy requirements are secured through forward contracts, granting the company a notable cost advantage over competitors in a volatile market. The stock market is responding moderately positively to this mix of rigorous restructuring and operational recovery. Shares have gained just over 7% since the start of the year, currently trading at €14.35.

Upcoming Milestones and Financial Targets

The urgency behind Evonik's drive to improve profitability is underscored by recent financial results. The company reported a return on capital employed (ROCE) of 6.1% for 2025, which remains significantly below its medium-term target of 11%.

The coming months will provide concrete data on the company's progress. Management will present first-quarter figures on May 8, offering insights into current demand trends. Additionally, the long-vacant position of Chief Financial Officer, empty since September, is expected to be filled by the Annual General Meeting on June 3. At that same meeting, shareholders will vote on the proposed transitional dividend of €1.00 per share for the past financial year.